Answers are grounded in this paper and cite their sources.
INTRODUCTION/AIMS: In the ADHERE trial (NCT04281472), subcutaneous (SC) efgartigimod PH20 provided clinical benefit in participants with worsening chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), regardless of prior CIDP treatment, including intravenous immunoglobulin (IVIg). Real-world data for efgartigimod PH20 SC treatment, which would not require worsening CIDP, are limited. METHODS: This is a case series of four patients diagnosed with typical CIDP between 3 and 12 months before start of study, who switched from IVIg (1 g/kg every 4 weeks) to efgartigimod PH20 SC (1000 mg weekly). RESULTS: Mean age was 59.3 years. At IVIg start, mean lower limb/upper limb (LL/UL) Inflammatory Neuropathy Cause and Treatment (INCAT) scores were 3.5/2.3 (range: 3-4/2-3), and Medical Research Council (MRC) sum score was 41.0 (range: 36-44). Despite early improvements in INCAT (mean LL/UL, 2.5/1.3 [range: 2-3/1-2]) and MRC (mean 47.5 [range: 42-54]) scores with IVIg, only one patient received IVIg for 6 months; three experienced unfavorable side effects, and one switched for convenience reasons. At the start of efgartigimod PH20 SC treatment, mean LL/UL INCAT scores were 2.3/1.3 (range: 2-3/1-2) and MRC sum score was 49.0 (range: 42-54); after 6 months, there were slight improvements in INCAT (mean LL/UL, 2.0/1.0 [range: 2-2/1-1]) and MRC (mean 51.5 [range: 48-54]) scores. Side effects were minimal in three patients and were not experienced by one patient. DISCUSSION: These results suggest that patients with CIDP being treated with IVIg can benefit from switching to efgartigimod PH20 SC treatment.
No takes yet. Share an insight, caveat, or question.
Raghav Govindarajan (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: